Lucid Diagnostics (LUCD) investor relations material

Market opportunity and product overview

• Offers a comprehensive, commercial-stage solution for esophageal precancer screening using EsoCheck (cell collection device) and EsoGuard (esophageal DNA test).

• Targets a $60 billion U.S. market with over 30 million at-risk GERD patients recommended for screening.

• EsoGuard is the first and only commercially available DNA test for widespread esophageal precancer detection, recommended in major clinical guidelines.

• Over 90% gross margin per test, with a Medicare payment of $1,938 per test.

• Early market adoption and a robust IP portfolio with multiple granted and pending patents in the U.S. and abroad.

Clinical need and solution effectiveness

• Esophageal cancer has a 22% five-year survival rate and a rapidly increasing incidence, with an estimated 16,250 U.S. deaths in 2025.

• Less than 5% of patients recommended for screening undergo endoscopy; EsoCheck offers a non-endoscopic, office-based alternative.

• EsoCheck is FDA 510k cleared, non-invasive, and achieves a 95% success rate with high patient satisfaction.

• EsoGuard uses next-generation sequencing to detect epigenetic changes, providing a positive or negative result within ~10 days.

• Clinical validation studies show EsoGuard sensitivity up to 96% and a 99% negative predictive value.

Commercial and operational strategy

• Focuses on primary care physicians, gastroenterologists, health systems, and health fairs for commercial adoption.

• Lucid-trained personnel support deployment in physician practices and health systems.

• Cumulative EsoGuard test volume has reached approximately 36,000 since launch, with growing claims paid and submitted.

• Near-term reimbursement milestones include a Multi-Jurisdictional Contractor Advisory Committee meeting and steps toward Medicare coverage.

• Strong consensus among medical experts supports nonendoscopic precancer testing for high-risk patients.